NanoString Appoints Elisha W. Finney to Board of Directors
May 10 2017 - 6:00AM
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life
science tools for translational research and molecular diagnostic
products, today announced the appointment of Elisha W. Finney,
former executive vice president and chief financial officer at
Varian Medical Systems (NYSE: VAR), to its Board of Directors and
Audit Committee. Ms. Finney brings more than 25 years of financial
and life science expertise to NanoString.
Her responsibilities at Varian included
corporate accounting; corporate communications and investor
relations; internal financial and compliance audit; risk
management; tax and treasury and corporate information systems. She
joined Varian in 1988 and was named vice president of finance and
CFO in April, 1999. In January, 2005, she was promoted to senior
vice president and given additional management responsibility for
the corporate information systems group. Ms. Finney was named
executive vice president of Varian in February, 2012. Ms. Finney
currently serves on the board of directors at ICU Medical
(NASDAQ:ICUI) and iRobot (NASDAQ:IRBT), and she previously served
as a board member at Altera Corporation, Thoratec and
Laserscope.
Ms. Finney earned her BA degree in risk
management and insurance from the University of Georgia as well as
an MBA degree from Golden Gate University in San Francisco.
“NanoString has a formidable combination of
proprietary technology and visionary leadership that has
established the company as an industry leader in translational
medicine and molecular diagnostics,” said Ms. Finney. “I’m excited
to have the opportunity to leverage my life science background and
capital market expertise to help contribute to NanoString’s
continued success.”
“Elisha brings decades of relevant life science
experience and financial acumen that will help guide our strategic
thinking as we grow the business and scale our operations,” said
president and chief executive officer, Brad Gray. “Elisha is a
well-respected leader in the life science industry, and we are
delighted to have her join our Board of Directors.”
About NanoString Technologies, Inc.
NanoString Technologies provides life science
tools for translational research and molecular diagnostic products.
The company's nCounter® Analysis System has been employed in life
sciences research since it was first introduced in 2008 and has
been cited in more than 1,500 peer-reviewed publications. The
nCounter Analysis System offers a cost-effective way to easily
profile the expression of hundreds of genes, proteins, miRNAs, or
copy number variations, simultaneously with high sensitivity and
precision, facilitating a wide variety of basic research and
translational medicine applications, including biomarker discovery
and validation. The company's technology is also being used in
diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature
Assay together with the nCounter Dx Analysis System is FDA 510(k)
cleared for use as a prognostic indicator for distant recurrence of
breast cancer. In addition, the company is collaborating with
multiple biopharmaceutical companies in the development of
companion diagnostic tests for various cancer therapies, helping to
realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the
NanoString logo, nCounter and Prosigna are trademarks or registered
trademarks of NanoString Technologies, Inc. in various
jurisdictions.
Contact:
Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768
ICU Medical (NASDAQ:ICUI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICU Medical (NASDAQ:ICUI)
Historical Stock Chart
From Apr 2023 to Apr 2024